Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer …
…, K Christian, L Sibylle, L Diana, PS Tjoung-Won… - The Lancet, 2020 - thelancet.com
Background Pembrolizumab monotherapy showed durable antitumour activity and manageable
safety in patients with metastatic triple-negative breast cancer. We aimed to examine …
safety in patients with metastatic triple-negative breast cancer. We aimed to examine …
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind …
…, A Floquet, H Hirte, A Amit, TW Park-Simon… - The lancet …, 2017 - thelancet.com
Background Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown
efficacy in a phase 2 study when given in capsule formulation to all-comer patients with …
efficacy in a phase 2 study when given in capsule formulation to all-comer patients with …
[HTML][HTML] Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 …
…, P Beale, A Cervantes, TW Park-Simon… - The Lancet …, 2015 - thelancet.com
Background The ICON7 trial previously reported improved progression-free survival in women
with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the …
with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the …
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies
…, JH Karstens, A Ay, TW Park-Simon… - Journal of the …, 2011 - academic.oup.com
Background Previous studies have suggested that breast cancer risk factors are associated
with estrogen receptor (ER) and progesterone receptor (PR) expression status of the tumors. …
with estrogen receptor (ER) and progesterone receptor (PR) expression status of the tumors. …
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis …
…, M Friedlander, A Baldoni, TW Park-Simon… - The Lancet …, 2021 - thelancet.com
Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously
been shown to extend progression-free survival versus placebo when given to patients with …
been shown to extend progression-free survival versus placebo when given to patients with …
Prediction of breast cancer risk based on profiling with common genetic variants
…, H Christiansen, TW Park-Simon… - Journal of the …, 2015 - academic.oup.com
Background: Data for multiple common susceptibility alleles for breast cancer may be combined
to identify women at different levels of breast cancer risk. Such stratification could guide …
to identify women at different levels of breast cancer risk. Such stratification could guide …
[HTML][HTML] Age-and tumor subtype–specific breast cancer risk estimates for CHEK2* 1100delC carriers
…, PA Newcomb, K Offit, TW Park-Simon… - Journal of clinical …, 2016 - ncbi.nlm.nih.gov
Purpose CHEK2* 1100delC is a well-established breast cancer risk variant that is most
prevalent in European populations; however, there are limited data on risk of breast cancer by …
prevalent in European populations; however, there are limited data on risk of breast cancer by …
[HTML][HTML] Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer …
Background Patients with HER2-positive early breast cancer (EBC) preferred subcutaneous
(sc) trastuzumab, delivered via single-use injection device (SID), over the intravenous (iv) …
(sc) trastuzumab, delivered via single-use injection device (SID), over the intravenous (iv) …
[HTML][HTML] Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)
…, J Sehouli, K Baumann, C Jackisch, TW Park-Simon… - PloS one, 2017 - journals.plos.org
Background Identification of families at risk for ovarian cancer offers the opportunity to
consider prophylactic surgery thus reducing ovarian cancer mortality. So far, identification of …
consider prophylactic surgery thus reducing ovarian cancer mortality. So far, identification of …
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
…, S Mahner, TM Meniawy, TW Park-Simon… - The Lancet …, 2020 - thelancet.com
Background State-of-the art therapy for recurrent ovarian cancer suitable for platinum-based
re-treatment includes bevacizumab-containing combinations (eg, bevacizumab combined …
re-treatment includes bevacizumab-containing combinations (eg, bevacizumab combined …